Keytruda is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby allows the immune system to destroy them
KEYTRUDA (PEMBROLIZUMAB) INDICATIONS:
Treatment of recurrent or metastatic cervical cancer in patients whose tumors express PD-L1 (combined positive score [CPS] ≥ 1), as determined by an approved test, and with disease progression on or after chemotherapy.
Treatment of recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy, and if appropriate, HER2/neu-targeted therapy.
For the treatment of unresectable or metastatic melanoma.
For the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection
Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy.
For treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.
Treatment of primary mediastinal large B-cell lymphoma (PMBCL) in adult or pediatric patients with refractory disease ow ho have relapsed after 2 or more prior lines of therapy.
For treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
For treatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
For treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors or colorectal cancer that have progressed following prior treatment.
For treatment of patients with hepatocellular cancer (HCC) who have been previously treatment with sorafenib.
For Treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell cancer.
DOSAGE FORM & STRENGTH:
Keytruda 50mg/vialWholesaler
Keytruda 200mg/4mL (25mg/mL) Supplier
Rasso Swiss Pharma is a Keytruda distributor, supplier and wholesaler.